A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed · Phase 2

Conditions studied: Acute Myelogenous Leukemia, Myelodysplastic Syndrome

In brief

The purpose of this study is to assess the effects of the combination of all-trans retinoic acid in combination with one of two schedules of Bryostatin 1 in patients with myelodysplasia and acute myelogenous leukemia.

Key facts

Study ID

NCT00136461

Run by

Dana-Farber Cancer Institute

People needed

40

Starts

1997-05-01

Expected to finish

2000-08-01

Last updated by the study team

2011-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with AML who have failed induction chemotherapy.
• Patients with secondary AML
• Patients with AML over age 60 who are deemed not to be a candidate for chemotherapy.
• Patients with any subtype of MDS.
• Age 18 or greater.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Satisfactory liver and kidney function.
• Greater than 4 weeks from prior chemotherapy or radiation therapy.

You may not qualify if…

• Central nervous system abnormality.
• Uncontrolled active infection.

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.